Stories

Life Sciences Market Trends Q4 2025

by Dennis Kirkpatrick and Mike Marston 3 minute read

The life sciences market remains optimistic.

2025 is rounding out to be one of the most transformative periods the life sciences industry has experienced.

While certain factors continue to limit growth in the research and development sector, the pace of manufacturing commitments, new project announcements, and project initiations are reaching unprecedented levels. Unpredictable and evolving market conditions are introducing significant decision-making complexities for project owners, but the life sciences market remains dynamic and poised for growth.

Market Trend Research and Development (R&D)’s Lasting Impacts

Two significant factors continue to shape the R&D project landscape. The current 2026 federal funding proposals are continuing a downward trend for NIH, CDC and NSF. In addition, the real estate oversupply and limited uptake of inventory in major U.S. R&D hubs are collectively dampening the life sciences R&D construction market.

Despite these broader challenges, several signs point toward a positive outlook for the market—novel drug approvals through October are aligning year over year with the 50 FDA drug approvals in 2024, the ongoing influence of AI in research, advancements in personalized medicines, economic influences such as lower interest rates, government investment incentives, and biotechnology stock index growth—are driving optimism. Additionally, there is emerging geography activity that was previously not anticipated, suggesting expansion beyond traditional markets. These factors signal moving past the recent downturn and into a period of renewed growth and opportunity.

Market Trend The Manufacturing Environment

Despite rising costs, aggressive schedules, and unpredictable market conditions, U.S. biopharmaceutical companies are proceeding with substantial investments in manufacturing.

These efforts are supported by recent presidential executive orders aimed at streamlining regulatory processes to promote domestic production of critical medicines, as well as initiatives to strengthen the American pharmaceutical supply chain by establishing a strategic reserve of active pharmaceutical ingredients (APIs).The domestic manufacturing sector is evolving rapidly, with expedited review and approval processes for facilities dedicated to APIs, large-scale bulk biologics, and fill-finish operations. While the eastern United States remains the primary investment region, emerging opportunities in the western half of the country are becoming increasingly apparent.

Overall, the architecture, engineering, and construction (AEC) market is experiencing unprecedented growth, and strategic partnerships and early engagement to secure skilled labor have proven to be the most effective approach for project success.

animated gif showing map of the United States and value of investments in life sciences

Onshoring cGMP Manufacturing

$20B+ Pharma Investment Announcements

Market Trend Constructing in unprecedented and unpredictable times

Data centers have been able to achieve rapid, high-quality builds by adopting forward-thinking execution methods, often completing projects in under two years. Both data centers and biopharma facilities share challenges like complex systems and specialized labor needs, but data centers currently outperform in speed-to-market. Adopting data center strategies could help pharmaceutical companies bring medicines to patients faster, with significant benefits for patient outcomes.

Early Engagement:	Early contractor involvement and empowering teams to make decisions are key to streamlining planning and reducing delays.	Involving contractors before site selection and design allows for better scheduling, labor planning, and supply chain management, especially securing critical equipment early.
Trusted Partnerships:	Build trusted partnerships with general contractors, leading to faster, more predictable project execution and shared risk.
Key Services:	Self-performing general contractors control labor resources and critical scopes, ensuring quality, safety, and schedule certainty, which is vital in locations lacking skilled trades.	General contractors with prefabrication capabilities can work to identify opportunities that enable faster schedules and dry-in, moving prefabrication from simply a construction method to a business advantage.

Beyond tariffs Smarter planning in project execution

To avoid delays, project teams are initiating design, procurement, and strategy discussions earlier in the timeline, ensuring alignment and addressing potential issues before they impact project schedules.

Planning and collaborating early among stakeholders—particularly in design, procurement, and contracting—are crucial for mitigating risks related to equipment sourcing, labor shortages, and pricing instability.
Shifting away from traditional delivery models toward more flexible and collaborative approaches, such as phased procurement and open-book negotiations, maintain momentum and adapt to changing conditions.
Avoiding common pitfalls such as replicating designs without site-specific adjustments, over-relying on prefabrication without early decision alignment, and underestimating the bandwidth needed for owner-side decision-making and facility operation.
Prioritizing early risk identification, adaptable vendor sourcing, and integrated CQV (commissioning, qualification, and validation) planning, enables teams to overcome delays and deliver facilities faster for patient benefit.